Moleculin Biotech, Inc. Warrants and Rights Outstanding
Moleculin Biotech, Inc. (MBRX) had Warrants and Rights Outstanding of $3.10 million as of 2018-09-30, per its 10-Q filed 2018-11-13.
Discontinued › Balance Sheet › Equity, Attributable to Parent
us-gaap:WarrantsAndRightsOutstanding · last filed 2018-11-13
- 2018-09-30: Warrants and Rights Outstanding $3.10M.
- 2018-06-30: Warrants and Rights Outstanding $3.70M.
| Period end | Warrants and Rights Outstanding |
|---|---|
| 2018-09-30 | $3.10M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $3.70M 10-Q · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |